Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, this warning letter was issued to Corporativo Bureli S.A. de C.V., a drug manufacturer or distributor, on December 1, 2020. Without access to the full letter text or subject line, the specific nature of the violations cannot be determined from the available information. The FDA took regulatory action against this company's drug products, though the particular manufacturing, labeling, or compliance issues involved remain unspecified in the provided metadata.